Biotech | June 01, 2022
Novavax initiates phase 3 trial of its COVID-19 omicron booster
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Subscribe To Our Newsletter & Stay Updated
